Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
First patient enrolled in a Phase Ib trial in patients with locally recurrent RAS-mutated rectal cancer Oslo, 20 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that it has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer scheduled to have surgery. The trial is being conducted at clinical sites in Australia and New Zealand. In this open label, non-randomized trial, ten